Document Type
Patent
Publication Date
May 2014
Patent Number
8716299
Abstract
A treatment for prostate cancer using cyclin-dependent kinase inhibitors is provided. The effects of cyclin-dependent kinase inhibitors on the survival of prostate cancer cells was examined. Roscovitine, R-roscovitine, and CGP74514A were shown to induce the apoptosis of LNCaP and LNCaP-Rf cells, both of which express wild-type p53. The cyclin-dependent kinase inhibitors of the present invention induce the mitochondria-mediated apoptosis of prostate cancer cells by a dual mechanism: p53 accumulation and XIAP depletion.
Application Number
11/306,241
Recommended Citation
Mohapatra, Subhra and Pledger, W. Jack, "XIAP-targeted prostate cancer therapy" (2014). USF Patents. 112.
https://digitalcommons.usf.edu/usf_patents/112
Assignees
University of South Florida
Filing Date
12/20/2005
Primary/U.S. Class
514/263
